Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

BACKGROUND: Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk, and rec...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cardiovasc Diabetol
Asıl Yazarlar: Lugner, Moa, Sattar, Naveed, Miftaraj, Mervete, Ekelund, Jan, Franzén, Stefan, Svensson, Ann-Marie, Eliasson, Björn
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2021
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983265/
https://ncbi.nlm.nih.gov/pubmed/33752680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01258-x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller